Latest progress in tyrosine kinase inhibitors

Tatiana V. Pospelova; Valery A. Pospelov

doi:10.18632/oncotarget.1836

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Latest progress in tyrosine kinase inhibitors

Tatiana V. Pospelova _ and Valery A. Pospelov

PDF | HTML | How to cite

Oncotarget. 2014; 5:1157-1161. https://doi.org/10.18632/oncotarget.1836

Metrics: PDF 1923 views | HTML 2237 views | ?

Abstract

Tatiana V. Pospelova1,2 and Valery A. Pospelov1,2

1 Institute of Cytology, Russian Academy of Sciences, St. Petersburg, Russia

2 Saint Petersburg State University, St. Petersburg, Russia

Correspondence:

Tatiana V. Pospelova, email:

Keywords: cancer, mTOR, kinases, c-Met, Bcr-Abl, senescence

Received: March 10, 2014 Accepted: March 20, 2014 Published: March 20, 2014

Abstract

Here we discuss the latest progress in development of some kinase inhibitors such as inhibitors of c-MET, LIM and Bcr-Abl kinases. Importantly, many oncogenic kinases signal via the mTOR pathway, suggesting a common target for drug combinations.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1836

Publication Alerts

Research Perspectives:

Latest progress in tyrosine kinase inhibitors

Abstract